Group 1 - The core viewpoint of the article highlights that Rebio Biotech (06938) is a leading player in China's small RNA field, recognized for its comprehensive technology platform and significant market potential, often referred to as the "Chinese version of Alnylam" [1] - Rebio Biotech has six self-developed siRNA drugs currently in clinical trials, targeting seven indications, with four of them in Phase 2 trials, and over 20 preclinical assets in progress [1] - The global thrombotic disease market is projected to impact approximately 26.7 million people by 2026, with an anti-thrombotic drug market valued at around $70 billion [1] Group 2 - The company's pipeline targets FXI, effectively avoiding bleeding risks associated with existing drugs, and siRNA offers long-lasting and safety advantages [1] - Rebio Biotech's pipeline has first-in-class (FIC) potential, having already entered Phase 2 clinical trials, specifically in a Phase 2a trial for coronary artery disease, with plans to initiate Phase 2b trials within the year [1] - Initial Phase 1 clinical data indicates that the company's product demonstrates superior anticoagulant effects with strong safety profiles, showing no serious adverse events related to the drug, with peak potential estimated to reach $10 billion [1]
瑞博生物-B午前涨超3% 公司管线具备FIC潜力 已经率先进入2期临床